The strong Phase 2 data significantly de-risks bezisterim's development path in Parkinson's disease and supports advancement to a pivotal Phase 3 trial. Traders should watch for the August 12 conference call for additional details and the upcoming ADDRESS-LC trial topline data expected late summer 2026, which could provide further catalysts.
Price Chart
Executive Summary
BioVie announced positive topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease. The trial met prespecified endpoints, showing statistically significant improvements on motor and non-motor symptoms, as well as favorable biomarker and safety profiles. These results provide a foundation for a potential Phase 3 trial design, representing a significant clinical catalyst for the company.
Key Facts
- Phase 2 SUNRISE-PD trial of bezisterim met prespecified endpoints in early Parkinson's disease.
- Patients showed statistically significant improvements on EPNIC-15 composite endpoint (p=0.0006) and MDS-UPDRS Parts I, II, and III.
- Bezisterim was well tolerated with a safety profile comparable to placebo (39.3% adverse events vs 51.7% for placebo).
- 283 of 380 proteins shifted in the direction of lower inflammatory burden (binomial p=3.2 X 10-22).
- Composite neuroinflammation measure improved with bezisterim (-0.28) vs placebo (+0.19) (Cohen's d = -1.06, p=0.0018).
- NfL levels decreased with bezisterim (-0.0148 log/week) vs increased with placebo (+0.0095 log/week) (p=0.008).
- Conference call scheduled for August 12, 2026 at 4:15 p.m. EDT to discuss results.
Financial Impact
Positive Phase 2 results in a large market (PD affects 10M+ people worldwide, $82.2B US economic burden in 2024) significantly de-risk bezisterim's clinical path and increase probability of regulatory success.
Risk Factors
- Phase 2 results (57 patients, 12 weeks) may not replicate in larger, longer-duration Phase 3 trials.
- All p-values are nominal and unadjusted for multiplicity, consistent with exploratory Phase 2 objectives.
- Biomarker and proteomic endpoints are exploratory; FDA has not validated these as surrogate endpoints for Parkinson's disease.
- Company is clinical-stage with no approved products and may require additional capital to fund Phase 3 trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001520138-26-000312 |
| Document: bivi-20260806_8k.htm | 0001520138-26-000312 |
| Document: 0001520138-26-000312-index-headers.html | 0001520138-26-000312 |
| Document: 0001520138-26-000312-index.html | 0001520138-26-000312 |
| Document: 0001520138-26-000312.txt | 0001520138-26-000312 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $1.37 | awaiting T+20 | — | $1.33 (−2.92%) |
Sep 15, 2026 6w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.33 (−24.00%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.33 (−13.68%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.33 (+1.48%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.33 (−1.48%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.33 (+17.90%) |
Jun 30, 2026 17w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.33 (+31.44%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.33 (−16.35%) |
Apr 14, 2026 28w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.33 (−8.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers